MBA/Biomedical Entrepreneurship Track

This track within the MBA program connects the Tepper School’s Entrepreneurship Track with translational biomedical research training from the University of Pittsburgh School of Medicine.

PROGRAM OVERVIEW

The MBA/Biomedical Translational Research and Entrepreneurship Program leverages two top tier university programs located in Pittsburgh — the MBA program at the Tepper School of Business at Carnegie Mellon University and translational research training at the University of Pittsburgh School of Medicine. This confluence provides a unique and differentiated opportunity to educate business savvy physicians and medical research professionals, and to link their research undertakings to market-driven solutions that will drive healthcare innovations in the 21st century. The program prepares leaders who are poised to make significant contributions to the broader biomedical community of innovators.

The program is designed to educate candidates as business innovators and leaders steeped in the economics, entrepreneurship, management, marketing and commercialization of medical innovations, while also immersing them in the science and technology involved in translational research and clinical/laboratory implementation. Candidates will understand how to guide healthcare, science, and business into a new entrepreneurial age.

This collaborative program is offered by the Tepper School of Business and the Institute for Clinical Research Education (ICRE) under the University of Pittsburgh’s School of Medicine and Schools of the Health Sciences.

PROGRAM STRUCTURE

The MBA/Biomedical Translational Research and Entrepreneurship program is a two-to-three year comprehensive course of study beginning in August. Students in this program will enroll in either the part-time on-campus or full-time MBA program and join the MBA/Biomedical Entrepreneurship track. All students will be immersed for a minimum of 15 months in a T1 translational research environment within laboratories at the University of Pittsburgh School of Medicine to acquire hands-on biomedical experience in preparation for moving novel drugs, devices or informatics solutions from the laboratory to clinical practice work. Students will be enrolled in the ICRE Entrepreneurial MBA Translational Research Training Program, acquiring knowledge in research techniques, literature review, drug and device commercialization processes, institutional regulatory bodies, clinical trials, and funding opportunities.

The Tepper MBA requires 192 units of coursework. In this program, credit is earned via 96 units of required core courses (16 half-semester courses), 66 units of electives (11 half-semester electives), and 30 non-tuition-bearing units associated with student’s completion of the ICRE Entrepreneurial MBA Translational Research Training Program. The school will award qualifying participants in the program a tuition scholarship.

ADMISSIONS

In order to participate in the MBA/Biomedical Translational Research and Entrepreneurship Program, applicants must first apply and be accepted into the Tepper MBA program and express interest in the MBA/Biomedical Entrepreneurship track. Applications are accepted throughout the year and the deadlines are the same as the Tepper MBA full-time and part-time programs; learn more about application deadlines. Space is limited, and students who are accepted from the Tepper School of Business must also meet requirements for participation in the University of Pittsburgh’s School of Medicine/Schools of the Health Sciences ICRE training program.

Students should contact Arthur Boni if they are interested in applying to the MBA/Biomedical Entrepreneurship track within the Tepper MBA program. Each applicant is required to take the Graduate Management Admission Test (GMAT) or the Graduate Record Examination (GRE) test.

For additional information, please contact the Tepper Masters Admissions office and, for specific questions regarding the Entrepreneurial MBA Translational Research Training Program, please email Chris O’Donnell.